Specific tools for targeting and expression in Müller glial cells
Author(s) -
Lucie P. Pellissier,
Robert M. Hoek,
Rogier M. Vos,
Wendy M. Aartsen,
R. R. Klimczak,
Stefan A. Hoyng,
John G. Flannery,
Jan Wijnholds
Publication year - 2014
Publication title -
molecular therapy — methods and clinical development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.285
H-Index - 32
ISSN - 2329-0501
DOI - 10.1038/mtm.2014.9
Subject(s) - biology , promoter , microbiology and biotechnology , capsid , muller glia , transduction (biophysics) , retinal , virology , gene , gene expression , virus , genetics , stem cell , progenitor cell , biochemistry
Despite their physiological roles, Müller glial cells are involved directly or indirectly in retinal disease pathogenesis and are an interesting target for therapeutic approaches for retinal diseases and regeneration such as CRB1 inherited retinal dystrophies. In this study, we characterized the efficiency of adeno-associated virus (AAV) capsid variants and different promoters to drive protein expression in Müller glial cells. ShH10Y and AAV9 were the most powerful capsids to infect mouse Müller glial cells. Retinaldehyde-binding protein 1 (RLBP1) promoter was the most powerful promoter to transduce Müller glial cells. ShH10Y capsids and RLBP1 promoter targeted human Müller glial cells in vitro. We also developed and tested smaller promoters to express the large CRB1 gene via AAV vectors. Minimal cytomegalovirus (CMV) promoter allowed expression of full-length CRB1 protein in Müller glial cells. In summary, ShH10Y and AAV9 capsids, and RLBP1 or minimal CMV promoters are of interest as specific tools to target and express in mouse or human Müller glial cells
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom